Coherus Biosciences presents data from next-generation immuno-oncology programs

Coherus BioSciences announced data from three immuno-oncology pipeline programs at the 38th Annual Meeting of SITC taking place November 1 – 5, 2023 at the San Diego Convention Center in San Diego, CA. Preclinical data presented support differentiated mechanisms of its next-generation immunotherapies potentially enabling the antitumor immune activation in more cancer patients and enhanced treatment outcomes. “These data presented at SITC highlight the complementary mechanisms that we have in our innovative immunotherapy portfolio, including anti-PD-1, anti-IL27 and anti-CCR8, and the promise of novel immuno-oncology treatment combinations that may overcome the challenging tumor microenvironment,” said Theresa LaVallee, Ph.D., Coherus’ chief development officer. “LOQTORZI(TM) is the first approved treatment option for patients with nasopharyngeal carcinoma, and we will continue to generate and use data to optimize our clinical development plans through the selection of additional tumor types and immuno-oncology combinations that can have the greatest impact on extending survival for cancer patients.”